Free Trial

BioNTech (BNTX) Competitors

BioNTech logo
$110.02 -1.02 (-0.92%)
Closing price 04:00 PM Eastern
Extended Trading
$110.45 +0.43 (+0.39%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BNTX vs. GSK, TAK, ARGX, ONC, INSM, SMMT, TEVA, ITCI, GMAB, and MRNA

Should you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

BioNTech vs. Its Competitors

GSK (NYSE:GSK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

GSK presently has a consensus target price of $37.38, indicating a potential upside of 3.02%. BioNTech has a consensus target price of $136.58, indicating a potential upside of 24.14%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than GSK.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
1 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.11
BioNTech
0 Sell rating(s)
4 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.83

GSK has a net margin of 9.89% compared to BioNTech's net margin of -27.37%. GSK's return on equity of 48.82% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
GSK9.89% 48.82% 11.15%
BioNTech -27.37%-3.94%-3.41%

15.7% of GSK shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK$40.10B1.85$3.29B$1.9418.70
BioNTech$2.98B8.88-$719.92M-$3.40-32.36

In the previous week, GSK had 23 more articles in the media than BioNTech. MarketBeat recorded 32 mentions for GSK and 9 mentions for BioNTech. BioNTech's average media sentiment score of 0.56 beat GSK's score of 0.45 indicating that BioNTech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
10 Very Positive mention(s)
8 Positive mention(s)
4 Neutral mention(s)
5 Negative mention(s)
5 Very Negative mention(s)
Neutral
BioNTech
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

GSK has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Summary

GSK beats BioNTech on 9 of the 16 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BNTX vs. The Competition

MetricBioNTechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$26.69B$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E Ratio-32.368.2821.0120.09
Price / Sales8.88303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book1.267.678.125.65
Net Income-$719.92M-$55.28M$3.25B$257.91M
7 Day Performance-2.54%2.50%0.97%2.09%
1 Month Performance5.38%11.70%7.36%11.13%
1 Year Performance27.38%4.89%31.31%18.40%

BioNTech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BNTX
BioNTech
1.4591 of 5 stars
$110.02
-0.9%
$136.58
+24.1%
+28.4%$26.69B$2.98B-32.366,772Analyst Forecast
GSK
GSK
1.9089 of 5 stars
$38.34
+0.1%
$37.38
-2.5%
-8.4%$78.49B$40.10B19.7668,629Trending News
TAK
Takeda Pharmaceutical
2.0054 of 5 stars
$15.04
+2.4%
N/A+7.6%$47.84B$30.09B68.3447,455Positive News
High Trading Volume
ARGX
argenex
4.4966 of 5 stars
$561.28
+0.2%
$728.06
+29.7%
+23.6%$34.35B$2.25B34.631,599Positive News
Analyst Revision
ONC
BeOne Medicines
2.5583 of 5 stars
$252.14
+0.7%
$320.67
+27.2%
N/A$27.63B$3.81B-67.7811,000Analyst Forecast
Gap Up
INSM
Insmed
3.8659 of 5 stars
$101.89
+3.8%
$108.07
+6.1%
+37.9%$19.33B$381.03M-17.121,271Positive News
Analyst Forecast
Insider Trade
SMMT
Summit Therapeutics
2.886 of 5 stars
$25.40
+1.6%
$34.67
+36.5%
+196.8%$18.86BN/A-74.70110
TEVA
Teva Pharmaceutical Industries
4.1195 of 5 stars
$16.43
+0.2%
$24.71
+50.5%
-0.4%$18.84B$16.54B-14.2836,830
ITCI
Intra-Cellular Therapies
0.9187 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.9168 of 5 stars
$21.46
+0.3%
$37.80
+76.1%
-18.0%$13.77B$3.12B12.192,682Analyst Revision
MRNA
Moderna
4.2835 of 5 stars
$32.87
-2.3%
$46.61
+41.8%
-74.0%$12.71B$3.24B-3.775,800Trending News
Options Volume
Analyst Revision

Related Companies and Tools


This page (NASDAQ:BNTX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners